PRESS RELEASE

Cipla invests in Chase Pharmaceuticals to support Alzheimer’s disease drug development

India, Mumbai, May 12th, 2014: Cipla Limited, a global healthcare company which uses cutting edge technology and innovation to meet the everyday needs of all patients, today announced its investment in Chase Pharmaceuticals Corporation Inc., US (“Chase”), through its wholly owned subsidiary, Cipla (EU) Limited, UK. Chase is an early stage drug development company, based in Washington DC. Chase is focused on developing novel approaches to improve treatments for Alzheimer’s disease. It has a unique patented approach and is focused on improving the efficacy, safety and tolerability of existing Alzheimer medications.

Cipla – through its impact investment unit Cipla New Ventures – is investing in the Series B round of financing as part of a syndicate, which also consists of Edmond de Rothschild Investment Partners and New Rhein Healthcare LLC. Cipla New Ventures was set up to chart a trajectory in innovation around biologicals, repurposing existing safe drugs and leveraging Cipla’s enviable suite of delivery technologies through disruptive innovation around access and affordability. It is managed by Mr. Chandru Chawla.

The $21 million two-phase financing will support Phase 2a and Phase 2b clinical trials for Chase’s lead drug CPC 201. The original venture funding for Chase was provided by the Brain Trust Accelerator Fund in 2010.

Commenting on the investment, Mr. Subhanu Saxena, MD & Global CEO, Cipla Ltd said: “This investment is consistent with Cipla New Ventures’ mission to build more innovation-led business streams for Cipla in the future. We want to bring affordable medicines, where we identify an unmet patient need, in a way that leverages Cipla’s formidable technology, device and development capabilities.”

In India, over 5 million patients suffer from dementia, most of whom are afflicted with Alzheimer’s. These numbers are expected to double by 2030. In India, the caregiver is the family and the economic and social impact is far reaching. In North America, Alzheimer’s disease affects more than over 7 million patients and its impact is growing as the population ages. The disease costs the US alone $203 billion annually with projections to reach $1.2 trillion by 2050.

In addition to financing Chase, Cipla will collaborate with the company to develop the drug. If successful, Cipla may provide low cost access to Chase’s lead drug in India and South Africa where Cipla has championed affordable access to essential and life-saving medications for decades.
About Cipla Limited:
Cipla Limited is a global healthcare company which uses technology and innovation to meet every day needs of all patients. For more than 70 years, Cipla has emerged as one of the most respected pharmaceutical names in India as well as across more than 170 countries. Our portfolio includes 2000 products in 65 therapeutic categories with one quality standard globally. Cipla’s turnover in 2012-13 was 1.5 billion USD.

Whilst delivering a long-term sustainable business, Cipla recognises its duty to provide affordable medicines. Cipla’s emphasis on access for patients was recognized globally for the pioneering role played in HIV/AIDS treatment as the first pharmaceutical company to provide a triple combination anti-retroviral (ARV) in Africa at less than one dollar a day and thereby treating many millions of patients since 2001.

Cipla’s research and development focuses on developing innovative products and drug delivery systems and has given India and the world many ‘firsts’ for instance Triomune. In a tightly regulated environment, the company’s manufacturing facilities have approvals from all the main regulators including US FDA, UK MHRA, WHO, MCC, ANVISA, and PMDA which means the company provides one universal standard both domestically and internationally.

About Cipla (EU) Limited:
Cipla (EU) Limited, UK is a wholly owned subsidiary of Cipla Limited.

About Chase:
Chase is an early stage drug development company, based in Washington, DC. Its mission is to improve the quality of life for those suffering from disorders of brain function, especially cognitive dysfunction of the Alzheimer’s type. In the service of this goal, Chase Pharmaceuticals seeks to advance the development of its own intellectual property towards commercial products that satisfy crucial unmet medical needs. Current efforts, focused on pharmaceuticals for Alzheimer type dementia, include oral medications such as its lead product, CPC-201, as well as CPC-260 for transdermal administration. The privately held company received Series A funding from Brain Trust Accelerator Fund in support of its program of Phase I clinical trials. Chase was founded in 2007 by Thomas Chase, MD, former Scientific Director, National Institute of Neurological Disorders and Stroke (NINDS) and Kathleen Clarence-Smith, MD, PhD former head of CNS development at Sanofi, Roche and Otsuka.

About New Rhein Healthcare LLC:
New Rhein is a private equity investment firm focused on healthcare therapeutics and medical devices. Its partners and associates are former industry executives with operational and transactional experience. New Rhein invests in businesses which utilize proven products in new applications (e.g. new indications, new dosage forms, 505(b2)). The company compiles syndicates of operational focused investors who together bring a wealth of experience and a broad network of relationships to support its portfolio companies in development, regulatory, reimbursement, marketing and/or contract manufacturing. New Rhein provides an understanding on what would be attractive to strategic partners and works backwards to help
its portfolio companies build their value proposition. Prior New Rhein investments have included ophthalmic pharmaceuticals, molecular diagnostics and respiratory drug/device inhalers.

**About Edmond de Rothschild Investment Partners:**
Paris-based Edmond de Rothschild Investment Partners is the private equity affiliate of the Edmond de Rothschild Group, which is specialized in asset management and private banking. Edmond de Rothschild Investment Partners is dedicated to minority investments into privately-owned companies. It has currently close to EUR1 billion under management which is being invested primarily as life sciences venture capital and growth capital. Its Life Sciences Team of eight professionals brings together over 60 years of experience in the Life Science industry and more than 100 years of private equity and venture capital experience. The team has raised over EUR450 million through its Biodiscovery franchise and is currently investing BioDiscovery 4. For more information please visit: [www.edrip.fr](http://www.edrip.fr)

**About Brain Trust Accelerator Fund:**
The Brain Trust Accelerator Fund focuses on early stage investments that address the diagnosis and treatment of brain related diseases. Founded in 2006, the fund has provided both capital and resources for diagnostic, device and therapeutic companies developing technologies to deliver therapeutics across the blood brain barrier, a common barrier for treating many brain diseases; technologies to help optimize therapies that are most likely to benefit selected patients, often referred to as personalized medicine; and molecularly targeted therapies that target the abnormal pathways implicated in a variety of brain related disorders.

**Media Contact:**
Jaisingh Krishnan: +91 9833836185
Charlotte Chunawala: +91 7506257377

**Investor Relations:**
Anant Atal – Anant.Atal@Cipla.Com